- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | IO Biotech advances cancer vaccine candidate IO112 | 1 | Investing.com | ||
| Di | IO Biotech treibt Krebsimpfstoff-Kandidaten IO112 voran | 1 | Investing.com Deutsch | ||
| Di | IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate | - | GlobeNewswire (USA) | ||
| 09.01. | IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer | 107 | GlobeNewswire (Europe) | -- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 27.12.24 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.12.24 | Medizinischer Leiter von IO Biotech erwirbt Stammaktien im Wert von 26.553 US-Dollar | 3 | Investing.com Deutsch | ||
| IO BIOTECH Aktie jetzt für 0€ handeln | |||||
| 24.12.24 | IO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in Stock | 4 | MarketBeat | ||
| 20.12.24 | IO Biotech announces up to €57.5M debt financing from the European Investment Bank | 2 | Seeking Alpha | ||
| 20.12.24 | IO Biotech secures €57.5 million EIB loan for cancer vaccines | 1 | Investing.com | ||
| 20.12.24 | IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank | 1 | GlobeNewswire (USA) | ||
| 16.12.24 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.24 | IO Biotech stock hits 52-week low at $0.73 amid market challenges | 2 | Investing.com | ||
| 21.11.24 | IO Biotech-Aktie erreicht 52-Wochen-Tief bei 0,73 US-Dollar | 2 | Investing.com Deutsch | ||
| 12.11.24 | IO Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.24 | IO Biotech GAAP EPS of -$0.36 misses by $0.09 | 1 | Seeking Alpha | ||
| 12.11.24 | IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights | 124 | GlobeNewswire (Europe) | Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced... ► Artikel lesen | |
| 07.11.24 | Promising results for IO Biotech's cancer vaccine | 1 | Investing.com | ||
| 07.11.24 | IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic ... | 86 | GlobeNewswire (Europe) | -- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response... ► Artikel lesen | |
| 04.10.24 | IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16.09.24 | Piper Sandler hält an Overweight-Einstufung für IO Biotech fest | 7 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,790 | +0,77 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| BIOXXMED | 0,982 | -9,07 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Deutsche Wohnen, fox e-mobility, Linus Digital, ThyssenKrupp, Vonovia | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| ORGANOVO | 0,311 | -2,97 % | Organovo, Inc.: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease... ► Artikel lesen | |
| OCUGEN | 0,703 | -1,26 % | Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa | MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,038 | 0,00 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,765 | -2,55 % | Bio-Gate: Prognose reduziert, Potenzial aber weiter hoch | Nach Darstellung von SMC-Research musste Bio-Gate wegen Auftragsverschiebungen die Jahresprognose für 2024 reduzieren. SMC-Analyst Holger Steffen sieht immer noch hohes Potenzial in dem Geschäft, aber... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,750 | 0,00 % | Best of BioTech 2025 - BioNTech, Bayer, Pfizer, BioNxt, Defence Therapeutics, Evotec und Vidac Pharma | Die biotechnologische Forschung wird 2025 von mehreren maßgeblichen Trends, Technologien und gesellschaftlichen Herausforderungen geprägt sein. Unter Einsatz von Wissen und Geld verspricht sich die... ► Artikel lesen | |
| VAXART | 0,653 | -4,88 % | Vaxart, Inc.: Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial | Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,060 | +4,51 % | Burcon NutraScience Corporation: Burcon Agrees to Terms with its Alliance Partner for a Protein Production Facility | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,974 | +1,04 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| IMMUNIC | 0,936 | +2,86 % | EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in February | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor and Scientific Conferences in February
04.02.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,177 | +2,31 % | AIM ImmunoTech Inc. - S-1/A, General form for registration of securities | ||
| T2 BIOSYSTEMS | 0,224 | 0,00 % | T2 Biosystems stock plunges to 52-week low of $0.22 | ||
| CELLECTAR BIOSCIENCES | 0,250 | +1,63 % | Cellectar Biosciences, Inc. - 8-K, Current Report | ||
| CEL-SCI | 0,365 | -1,67 % | CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer | VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
"We... ► Artikel lesen |
IO BIOTECH INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,915 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IO BIOTECH INC finden Sie auf Wallstreet Online.
